how does hbv interact with the immune...
TRANSCRIPT
Department of Medicine II, Medical Center - University of Freiburg, Germany
Robert Thimme
How does HBV interact with the immune system?
Components of immune responses against HBV
Dendritic cells
NK cells
CD4+ T cells
Immunoregulatorycytokines
IL10
TGFβ
Innate immunityIFNα
CD8+ T cells
Hepatocytes
Treg
CD8+ T-cell responses in HBV infection
CD8+
weeks after infection
HBV DNA
T-ce
ll re
spon
se
0 2 4 6 8 10 12 14 16 18 20 22
T-cells
Depletion of CD8+ T cells prolongs viremia
Thimme, Chisari, J Virol 2003
weeks after infection
HBV DNA
T-ce
ll re
spon
se
Maini, Bertoletti Gastro 2001Boettler, Thimme, J Virol 2005
0 2 4 6 8 10 12 14 16 18 20 22
Temporal association of CD8+ T-cell responseand viral load
Intrahepatic accumulation of CD8+ T-cellresponses during viral clearance
Thimme, Chisari, J Virol 2003
viral load CD8 & AST
chronic phase
Thimme et al. J. Virol. 2003
cytolytic mechanisms
Function of CD8+ T cells in HBV
HBV infected hepatoma cellCD8+ T cell
Untreated control Direct co-culture Transwell cultures
- + stimulation
core18-27 peptide
Identifcation of a novel immunological cell culturemodel
Reduction of viral loads requires cell killing
Hoh et al. J Virol 2015
HBV
DNA
AST [U/L]
10 8
10 9
10 1 0
10 1 1
0
15
30
45
60
75
cytoplasmic HBV DNAAST
*
Δt = 96 hE:T = 1:1
untreated direct
Reduction of viral loads requires cell killing
Hoh et al. J Virol 2015
rel.
HBV
DNA AST [U/L]
10 8
10 9
10 1 0
10 1 1
0
15
30
45
60
75
cytoplasmic HBV DNAAST
*
Δt = 96 hE:T = 1:1
Strong reduction (95%) of viral loads requires:
• Direct cell-cell contact• Cytotoxic effector mechanisms
% re
mai
ning
vira
l DNA
0
20
40
60
80
100
p < 0.001
p < 0.05
HBeA
g PE
IU/m
l
0
10
20
30
40
50
HBeAg
HBsA
g [IU
/ml]
0
5
10
15
HBsAg
n = 2
CD8+ T-cell failureImmune responses in chronic HBV infection
priming
Treg cells
CD4+ T cells
immunoregulatorycytokines
IL10
TGFβ
TCR
antigen
CD8+ T cells exhaustion
viral escape
NK cells
CD8+ T-cell failureImmune responses in chronic HBV infection
priming
Treg cells
CD4+ T cells
immunoregulatorycytokines
IL10
TGFβ
TCR
antigen
CD8+ T cells exhaustion
viral escape
NK cells
Fate of virus-specific CD8+ T cells in acute andchronic infections
Acute:
Chronic:Exhausted:short-livedantigen-dependentfunctionally exhausted
Memory:long-livedantigen-independentpolyfunctional
Effector:short-livedantigen-dependentpolyfunctional
Heterogeneous populations -lessons from mouse model:• TbetdimEomeshi / TbethiEomesdim
(Paley, Science 2012)
• TCF1+ memory-like(Utzschneider, Nature Immunology 2013)
• CXCR5+ progenitor(Im & He, Nature 2016)
Aim of Study
Heterogeneity of virus-specific CD8+ T-cell populations in humans: chronic HBV and HCV infection
Inhibitory Receptors ↑↑↑• PD1• 2B4• TIGIT• KLRG1
Proliferation ↓↓↓
Cytokines↓↓↓ CD39 ↑↑↑
CD127 ↓↓↓(IL-7 Receptor)
Eomes↑↑Tbet ↓TCF1↓
Patient cohorts
cHBV (n=12):
• 7 inactive carriers− treatment naive
− low viral load: 779 IU/ml
(136 – 2149)
− no cirrhosis
• 5 patients with NUC therapy− low viral load: 19 IU/ml
(<10 – 33)
− no cirrhosis
cHCV (n=8):
• HCV genotype 1
• Viral load: 3213771 IU/ml
(42241 – 15x106)
• no cirrhosis
Alanio et al., Blood 2010Schmidt et al., J Virol 2011Nitschke et al., J Virol 2015
+PBMCs
epitope-specifictetramer
fluorochrome
magnetic anti-fluorochrome
microbeadlabeled PBMCs
PBMCs with enrichedepitope-specific T cells
magnetic-activated cell separation column
flow cytometric analysis
Magnetic bead enrichment of virus-specific CD8+ T cellsEnhanced resolution and potential for in-depth analysis of rare T-cell populations
Alanio et al., Blood 2010Schmidt et al., J Virol 2011Nitschke et al., J Virol 2015
+PBMCs
epitope-specifictetramer
fluorochrome
magnetic anti-fluorochrome
microbeadlabeled PBMCs
PBMCs with enrichedepitope-specific T cells
magnetic-activated cell separation column
flow cytometric analysis
Magnetic bead enrichment of virus-specific CD8+ T cellsEnhanced resolution and potential for in-depth analysis of rare T-cell populations
virus-specificCD8+ T cells
Before enrichment After enrichment
MF
I P
D1
H B V H C V0
2 0 0 0
4 0 0 0
6 0 0 0* *
PD1
tetra
mer
PD1
HBVHCV
CD8+
%E
om
esh
igh
H B V H C V0
2 0
4 0
6 0
8 0
1 0 0 * *
%C
D3
9+
H B V H C V0
2 0
4 0
6 0
8 0
1 0 0 *
Eomeshigh CD39
tetra
mer
Eomes
tetra
mer
CD39
Eomes CD39PD1
HBV: inactive carriers
HBV: patients withNUC therapy
HCV
HBV-specific CD8+ T cells lack terminal exhaustion markers
CD
127
PD1
HCVCD8+
HCV44.5
55.5
%C
D1
27
+P
D1
+
of
tet+
CD
8+
T c
ells
H B V H C V0
2 0
4 0
6 0
8 0
1 0 0**
%C
D1
27
- PD
1+
of
tet+
CD
8+
T c
ells
H B V H C V0
2 0
4 0
6 0
8 0
1 0 0***
CD127+PD1+CD127-PD1+
CD
127PD1
HBV98.6
0.8
CD8+
HBV
HBV-specific CD8+ T cells are predominantly CD127+PD1+
CD127+PD1+subset dominates in HBV-specific CD8+ T-cell populations
HBV: inactive carriers
HBV: patients withNUC therapy
HCV
terminallyexhausted
less differentiated„memory-like“
CD
127
PD1
CD127+PD1+
Eomeslow
CD39-
TCF1high
CD127-PD1+
Eomeslow
CD39+
TCF1dim
Immunity 2016
Two subsets of exhausted virus-specific CD8+ T cells in HCV but not HBV
Fate of terminally exhausted CD8+ T cells after antigen elimination?
HBV
HCV
Baseline EOT
CD8+
HCV
CD
127
PD1
CD8+
HCV49
28 21
73
23 1
B a se line
E OT
F U1 2
0
2 0
4 0
6 0
8 0
1 0 0
%C
D1
27
- PD
1h
i
********
CD127/PD1 subsetsLess
differentiatedTerminallyexhausted
B ase line
E OT
F U1 2
0
2 0
4 0
6 0
8 0
1 0 0
%C
D1
27
+P
D1
+
******
C
DAA mediated antigen removal leads to disappearance of terminally exhausted HCV-specific CD8+ T cells
Dominik Wieland, in revision
0 2 0 4 0 6 0 8 0 1 0 00
1
2
3
% T C F 1 +
log
(E
xpa
ns
ion
In
de
x)
0.0006p =
0.4395r =
HCV
HBV: inactive carriers
HBV: patients withNUC therapy
TCF1+
%T
CF
1+
of
tet+
CD
8+
T c
ells
H B V H C V0
2 0
4 0
6 0
8 0
1 0 0 **
Proliferative capacity(14d in vitro expansion)
The memory marker TCF1 determines proliferative capacity of virus-specific CD8+ T cells
High proliferative capacity of HBV-specific CD8+ T cellscorrelates with increased TCF1 expression
HCV
HBV: inactive carriers
HBV: patients withNUC therapy
Bengsch / Thimme, J Hepatol 2014
PD-L1 blockade has the strongest effect
% n
orm
al. P
rolif
erat
ion
Nature 2016
T-cell subpopulations in chronicHBV and HCV infection
chronic HCV
Less differentiated/ memory-like
Terminal differentiated/
exhausted
chronic HBV
Determinant?
Lessdifferentiated/ memory-like
Terminal differentiated/
exhausted
Antigen recognition
CD39Eomes TCF1
VL: 30 405 IU/ml
CD
127
PD1
tetra
mer
CD39
tetra
mer
Eomes
tetra
mer
TCF1
HBVHCV
CD8+
Characteristics of T-cell subpopulations in chronicallyHBV-infected patients with high VL
Lack of terminally exhaustedHBV-specific CD8+ T cells isnot due to absent antigen
CD8+ T-cell failure
Immune responses to HBV
priming
Treg cells
CD4+ T cells
immunoregulatorycytokines
IL10
TGFβ
TCR
antigen
CD8+ T cells exhaustion
viral escape
NK cells
NK cells in chronic viral hepatitis
NK cell functional dichotomy in cHBVresponse to cytokine stimulation ↓↓
response to antibody-coated target cells ↑
HD cHBV
NK cell
cytokineresponsiveness ↓
IFNγ
cytokineresponsiveness ↑↑
IFNγ
ADCC ↑ADCC ↑↑
NK cell NK cellNK cell
NK cell
NK cell
NK cell
NK cellNK cell
NK cellNK cell
NK cellNK cell
NK cell
NK cellNK cell
NK cellNK cell
NK cell
NK cell NK cellNK cell
Oliviero et al., Gastroenterology 2009
NK cells in chronic viral hepatitis
NK cell functional dichotomy in cHBV
Oliviero et al., Gastroenterology 2009Béziat et al., EJI 2012
response to cytokine stimulation ↓↓response to antibody-coated target cells ↑
Increased frequencies of NKG2C+ NK cells in chronic viral hepatitis→ linked to CMV seropositivity
HD cHBV
NK cell
NK cell NK cellNK cell
NK cell
NK cell
NK cell
NK cellNK cell
NK cellNK cell
NK cellNK cell
NK cell
NKG2C ↑
NK cellNK cell
NK cellNK cell
NK cell
NK cell NK cellNK cell
CMV
cytokineresponsiveness ↓
IFNγ
cytokineresponsiveness ↑↑
IFNγ
ADCC ↑ADCC ↑↑
Conventional vs. adaptive NK cells
adaptive NK cell
CD3ζ
NKG2C ↑
Helios ↓PLZF ↓
FcεRIγ
conventional NK cell
FcεRIγ
CD3ζHeliosPLZF
CD16CD16
Lee J et al., Immunity 2015Schlums H et al., Immunity 2015
ADCC ↑ADCC ↑↑
CMV
→ epigenetic regulation
cytokineresponsiveness ↓
IFNγ
cytokineresponsiveness ↑↑
IFNγ
Aim of Study
Is altered NK cell function in cHBV patients linked to an
expansion of adaptive NK cell subsets?
adaptive NK cell
conv.NK cell
adaptive NK cell
conv.NK cell
conv.NK cell
conv.NK cell
conv.NK cell
conv.NK cell
adaptive NK cell
adaptive NK cell
adaptive NK cell
adaptive NK cell
adaptive NK cell
HBV
Study approachMethods
Multiparametric flow cytometry• Phenotypic analyses• Functional analyses of cytokine
production and degranulation after − cytokine stimulation with IL-12/IL-15
and IL-12/IL-18− CD16 crosslinking (plate-bound)
Epigenetic analyses (EpigenDx)− FCER1G promoter methylation− IFNG promoter methylation
Patient cohorts
cHBV (n=21):
• no cirrhosis
• age: 41 (18 – 68)
• viral load: 8657512 IU/ml (0 – 1.64x108)
• ALT: 43 IU/ml (11 – 304)
• treatment: 16 naïve, 5 NUC
HD (n=30):• age: 42 (24 – 63)
Downregulation of FcεRIγ in CD56dim NK cells of cHBV patients
H D c H B V0
2 0
4 0
6 0
8 0
1 0 0
%F
cε
RI γ
+
****
%FcεRIγ+
adaptive NK cell
CD3ζ
NKG2C ↑
Helios ↓PLZF ↓
FcεRIγCD16
ADCC ↑↑
IFNγ ↓
Adaptive NK cells lack FcεRIγ expressionLee et al., Immunity 2015Schlums et al., Immunity 2015
Downregulation of FcεRIγ in CD56dim NK cells of cHBV patients
p o s n e g p o s n e g 0
2 0
4 0
6 0
8 0
1 0 0
%F
cε
RI γ
+
*
*
HD cHBV
HCMV:
%FcεRIγ+
Adaptive NK cells lack FcεRIγ expressionLee et al., Immunity 2015Schlums et al., Immunity 2015
adaptive NK cell
CD3ζ
NKG2C ↑
Helios ↓PLZF ↓
FcεRIγCD16
ADCC ↑↑
IFNγ ↓
Downregulation of FcεRIγ in CD56dim NK cells of cHBV patients
p o s n e g p o s n e g 0
2 0
4 0
6 0
8 0
1 0 0
%F
cε
RI γ
+
*
*
HD cHBV
HCMV: FcεRIγN
KG
2C
CD56dim NK cells of HCMV+ cHBV
conventionalNK cells
adaptive NK cells
%FcεRIγ+
adaptive NK cell
CD3ζ
NKG2C ↑
Helios ↓PLZF ↓
FcεRIγCD16
ADCC ↑↑
IFNγ ↓
Adaptive NK cells lack FcεRIγ expressionLee et al., Immunity 2015Schlums et al., Immunity 2015
FcεRIγ deficiency in CD56dim NK cells of CMV+ cHBV patients correlates with other protein downregulations
adaptive NK cell
CD3ζ
NKG2C ↑
Helios ↓PLZF ↓
FcεRIγCD16
Transcriptional regulation of adaptive FcεRIγ- NK cellsLee et al., Immunity 2015Schlums et al., Immunity 2015
Helios is down-regulated in FcεRIγ- NK cells in chronic HBV
FcεRIγ
Hel
ios
CD56dim NK cells of HCMV+ cHBV
I
IIIII
IV
I II III IV0
2 0
4 0
6 0
8 0
1 0 0
% o
f C
D5
6d
im N
K c
ells
% FcεRIγ/Helios subsets
ADCC ↑↑
IFNγ ↓
FcεRIγ deficiency in CD56dim NK cells of CMV+ cHBV patients correlates with other protein downregulations
adaptive NK cell
CD3ζ
NKG2C ↑
Helios ↓PLZF ↓
FcεRIγCD16
Transcriptional regulation of adaptive FcεRIγ- NK cellsLee et al., Immunity 2015Schlums et al., Immunity 2015
Helios is down-regulated in FcεRIγ- NK cells in chronic HBV
FcεRIγ
Hel
ios
conventionalNK cells
adaptive NK cells
CD56dim NK cells of HCMV+ cHBV
I
IIIII
IV
% FcεRIγ/Helios subsets
I II III IV0
2 0
4 0
6 0
8 0
1 0 0
% o
f C
D5
6d
im N
K c
ells
ADCC ↑↑
IFNγ ↓
c o n v e n t io n a lN K c e lls
a d a p t iv eN K c e lls
0
2 0
4 0
6 0
8 0
1 0 0%
PL
ZF
+
****
%PLZF+
Are these FcεRIγ-Helios- CD56dim NK cells in CMV+cHBV patients adaptive NK cells?Analysis of the master regulator PLZF
PLZF
I
III
Transcriptional regulation of adaptive FcεRIγ- NK cellsLee et al., Immunity 2015Schlums et al., Immunity 2015
conventionalNK cells
adaptive NK cells
adaptive NK cell
CD3ζ
NKG2C ↑
Helios ↓PLZF ↓
FcεRIγCD16
ADCC ↑↑
IFNγ ↓
Functional analysis (cytokine responsiveness)
IL-12/IL-15
IL-12/IL-18
c o n v e n tio n a lN K c e lls
a d a p tiv eN K c e lls
0
2 0
4 0
6 0
8 0
%IF
Ny+
****
c o n v e n tio n a lN K c e lls
a d a p tiv eN K c e lls
0
2 0
4 0
6 0
8 0
% I
FN
y+
****
cytokine stimulation
%IFNγ+
%IFNγ+
adaptive NK cell
CD3ζ
NKG2C ↑
Helios ↓PLZF ↓
FcεRIγCD16
ADCC ↑↑
IFNγ ↓
Are these FcεRIγ-Helios- CD56dim NK cells in CMV+cHBV patients adaptive NK cells?
c o n v e n tio n a lN K c e lls
a d a p tiv eN K c e lls
0
1 0
2 0
3 0
4 0
5 0
%IF
Ny+
**
CD16 crosslink
CMV-seropositive donors
adaptive NK cells ↑
CMV-induced adaptive NK cells are present in the majority of cHBV patients
HD: 80% 20%cHBV: 30% 70%
adaptive NK cell
conv.NK cell
conv.NK cell
adaptive NK cell
conv.NK cell
conv.NK cell
conv.NK cell
conv.NK cell
conv.NK cell
adaptive NK cell
conv.NK cell
adaptive NK cell
conv.NK cell
conv.NK cell
adaptive NK cell
conv.NK cell
conv.NK cell
conv.NK cell
conv.NK cell conv.
NK cell
conv.NK cell
conv.NK cell
conv.NK cell
conv.NK cell
CMV-seropositive donors
adaptive NK cells ↑
cytokine responsiveness ↓IL-12/IL-15/IL-18 IL-12/IL-15/IL-18
IFNγ ↑↑
HD: 80% 20%cHBV: 30% 70%
adaptive NK cell
conv.NK cell
conv.NK cell
adaptive NK cell
conv.NK cell
conv.NK cell
conv.NK cell
conv.NK cell
conv.NK cell
adaptive NK cell
conv.NK cell
adaptive NK cell
conv.NK cell
conv.NK cell
adaptive NK cell
conv.NK cell
conv.NK cell
conv.NK cell
conv.NK cell conv.
NK cell
conv.NK cell
conv.NK cell
conv.NK cell
conv.NK cell
IFNγ ↓
CMV-induced adaptive NK cells are present in the majority of cHBV patients
IFNγ ↓
CMV-seropositive donors
adaptive NK cells ↑
cytokine responsiveness ↓IL-12/IL-15/IL-18 IL-12/IL-15/IL-18
HD: 80% 20%cHBV: 30% 70%
adaptive NK cell
conv.NK cell
conv.NK cell
adaptive NK cell
conv.NK cell
conv.NK cell
conv.NK cell
conv.NK cell
conv.NK cell
adaptive NK cell
conv.NK cell
adaptive NK cell
conv.NK cell
conv.NK cell
adaptive NK cell
conv.NK cell
conv.NK cell
conv.NK cell
conv.NK cell conv.
NK cell
conv.NK cell
conv.NK cell
conv.NK cell
conv.NK cell
Functional dichotomy:
increased/conserved cytotoxicity decreased IFNγ productionIFNγ ↑↑
CMV-induced adaptive NK cells are present in the majority of cHBV patients
Novel insights into immune responses against HBV
CD8+ T cells NK cells
• memory-like• TCF1high
• promising target for PD1 blockade• determinant?
CD3ζ
NKG2C ↑
Helios ↓PLZF ↓
FcεRIγCD16
ADCC ↑↑
CMV
cytokineresponsiveness ↓
IFNγ
• expansion of epigeneticallyregulated adaptive NK cells
• driving force?• cross-talk with CD8+ T cells?
InhibitoryReceptors ↑
Proliferation ↓
CD39 ↓
CD127 ↑↑
Eomesdim
TCF1high
Robert ThimmeMaike Hofmann
Kathrin HeimCharlotte HerchenröderKatharina HerzogAlexander HohCatharina KramerTony MatschullaSebastian MerkerPatricia Otto-MoraAnita SchuchÖzlem SogukpinarCatrin TauberDominik WielandBritta ZecherXin Zhou
Christoph Neumann-Haefelin
Aurelien BeisertJanine KemmingMichael Kiraithe
Department of Medicine II - University of Freiburg
Acknowledgements
All patients and volunteers!
Tobias Böttler
Kristi BashoMaike SmitsKatharina Zoldan
Nico Büttner
Katharina GrützmannMiriam Krimmer